BioMarin Pharmaceutical Inc

ISIN US09061G1013 Symbol BMRN Industry Biotechnology Sector Healthcare
BioMarin Pharmaceutical Price
83.37USD 1.08%
1y Low: 71.3
1y High: 131.9
1y Low: 71.3
1y High: 131.9
BioMarin Pharmaceutical Analyst Rating
Strong Buy
Strong Sell
Market Cap
13.6 B USD
Dividend Yield
Performance 1y
22.53 %

BioMarin Pharmaceutical Stock Chart

BioMarin Pharmaceutical Dividend Chart

BioMarin Pharmaceutical Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

BioMarin Pharmaceutical Performance

1 Week
1 Month
6.65 %
6 Months
7.62 %
Year to Date
4.43 %
1 Year
22.53 %
5 Years
2.08 %

BioMarin Pharmaceutical Revenue, EBIT, and Income

BioMarin Pharmaceutical Margins

BioMarin Pharmaceutical Shares Outstanding

Useful Links

Search Twitter: $BMRN, #BMRN

BioMarin Pharmaceutical Company Info

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Headquarter

770 Lindaro Street, 94901 San Rafael, CA, USA

BioMarin Pharmaceutical Price to Earnings Ratio (PE Ratio): 16.5

The current Price to Earnings Ratio of BioMarin Pharmaceutical is 16.5.
The PE Ratio is calcluated by dividing the current BioMarin Pharmaceutical share price (83.37 USD) by the earnings per share (4.5).

BioMarin Pharmaceutical Market Cap: 13.6 B USD

The current market cap of BioMarin Pharmaceutical is 13.6 B USD.

BioMarin Pharmaceutical Stock Price: 83.37 USD

The current stock price of BioMarin Pharmaceutical is 83.37 USD.

BioMarin Pharmaceutical ISIN: US09061G1013

The ISIN (International Securities Identification Number) of BioMarin Pharmaceutical is US09061G1013.

BioMarin Pharmaceutical Ticker Symbol: BMRN

The ticker symbol of BioMarin Pharmaceutical is BMRN.

BioMarin Pharmaceutical Address

The address of the BioMarin Pharmaceutical HQ is 770 Lindaro Street, 94901 San Rafael, CA, USA.